DC Field | Value | Language |
dc.contributor.author | Moscalenco, D. | |
dc.contributor.author | Goecke, T. | |
dc.contributor.author | Theodoridis, K. | |
dc.contributor.author | Adibekian, Z. | |
dc.contributor.author | Tudorache, I. | |
dc.contributor.author | Hilfiker, A. | |
dc.contributor.author | Haverich, A. | |
dc.contributor.author | Cebotari, S. | |
dc.date.accessioned | 2020-07-09T06:48:13Z | |
dc.date.available | 2020-07-09T06:48:13Z | |
dc.date.issued | 2016 | |
dc.identifier.citation | MOSCALENCO, D., GOECKE, T., THEODORIDIS, K., ADIBEKIAN, Z., TUDORACHE, I., HILFIKER, A., HAVERICH, A., CEBOTARI, S. Decellularized tissue engineered pericardium as replacement for tricuspid valve in cardiac surgery. In: MedEspera: the 6th Internat. Medical Congress for Students and Young Doctors: abstract book. Chișinău: S. n., 2016, p. 141-142. | en_US |
dc.identifier.isbn | 978-9975-3028-3-8. | |
dc.identifier.uri | http://repository.usmf.md/handle/20.500.12710/11185 | |
dc.description | Department of Cardiac, Thoracic, Transplantation and Vascular Surgery, Hannover Medical School, Hannover Germany and Leibniz Research Laboratories for Biotechnology and Artificial Organs (LEBAO), Hannover Medical School, Hannover, Germany, The 6th International Medical Congress for Students and Young Doctors, May 12-14, 2016 | en_US |
dc.description.abstract | Introduction: Tricuspid valve replacement is the last treatment choice in tricuspid valve
pathology. The choice to insert mechanical or bioprosthetic valve remains controversial. Both prostheses
have some limitations such as infection, risk of thromboembolism, need for life-long anticoagulation or
limited durability. The following study aimed to develop a novel tissue-engineered tricuspid valve based
on decellularized pericardium allograft.
Materials and methods: Fresh ovine pericardium was harvested at the local slaughter house and
decellularized using detergents. For disinfection all samples were treated for 24h with Phosphate
Buffered Solution supplemented with 1% gentamicin and 1% streptomycin. The effectiveness of
decellularization was evaluated by histological staining (hematoxylin-eosin, Movat’s Pentachrom and
Van Gieson), Isolectin B4 staining (a-gal xenoantigen) and by DNA-quantification. Two valvular
leaflets were manufactured out of decellularized pericardium and sutured ex-vivo into the tricuspid
annulus of an ovine heart and suspended on papillary muscles. Hydraulic test were performed to prove
valve competency.
Discussion results: After detergent treatment pericardial tissue has been converted in a cell-free
scaffold as proven by standard histological analysis. Immunofluorescent examinations revealed the
absence of a-gal xenoantigens. DNA-quantification showed a substantial reduction in DNA content
compared to the normal tissue. The alignment of collagenous fibers in decellularized scaffolds appeared
well-preserved and was not affected by detergent decellularization procedure as proven by histological
staining. Graft disinfection and storage in antibiotic solution after decellularization did not affect the
texture of the scaffold. Furthermore, two leaflet structure created out of decellularized pericardium and
surgically sutured in tricuspid position of ovine heart resulted in a competent valve prosthesis.
Conclusion: The present results have shown successful decellularization of the ovine
pericardium using detergents. Decellularized pericardial allograft can be used in cardiac surgery as a
scaffold for valvular tissue engineering or for in-vivo guided tissue regeneration in tricuspid valve
replacement. | en_US |
dc.language.iso | en | en_US |
dc.publisher | MedEspera | en_US |
dc.subject | tissue engineering | en_US |
dc.subject | cardiac surgery | en_US |
dc.subject | tricuspid valve | en_US |
dc.subject | pericardium | en_US |
dc.title | Decellularized tissue engineered pericardium as replacement for tricuspid valve in cardiac surgery | en_US |
dc.type | Article | en_US |
Appears in Collections: | MedEspera 2016
|